Clinical Trials Browser

Healthy Volunteers

NCT01428635 2023-09-26

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Classical hematologyMyeloidOther hematologic neoplasm

Blast Crisis, Thrombocytopenia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Primary Myelofibrosis

NCT01168921 2023-03-23

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

23 enrolled 9 charts

Classical hematologyLymphoidOther hematologic neoplasm

Jacobs syndrome, Leukemia, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02323178 2021-04-20

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Phase 1/2 Completed

30 enrolled

Classical hematologyOther hematologic neoplasm

Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

NCT01893372 2020-02-18

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Phase 2 Completed

29 enrolled 12 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT01286675 2019-03-01

Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

Phase EARLY_PHASE1 Completed

19 enrolled

Plasma cell

Multiple Myeloma

NCT01610180 2018-07-16

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Phase 2 Completed

18 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Purpura, Thrombocytopenic, Idiopathic

NCT01488565 2016-02-15

Aza-E

Phase 2 Completed

25 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Clinical Trials

BCRPmarker

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Aza-E